Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Aliada Therapeutics logo — Beyond boundaries: Crossing the blood-brain barrier to creat...

Aliada Therapeutics

Beyond boundaries: Crossing the blood-brain barrier to create the next generation of central nervous system therapies

Founded 2021 United States Boston, United States 26 employees Venture round Total: $32.00M Biotechnology, Health Care +1

General Information

Company Name Aliada Therapeutics
Founded Year 2021
Location United States Boston, United States
Employees 26
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Aliada Therapeutics. To contact Aliada Therapeutics, visit aliadatx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Aliada Therapeutics compare?

A PDF of Aliada Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Aliada Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Aliada Therapeutics

Aliada Therapeutics is a biotechnology startup that aims to revolutionize the treatment of central nervous system (CNS) diseases by overcoming the challenge of crossing the blood-brain barrier. With the slogan "Beyond boundaries: Crossing the blood-brain barrier to create the next generation of central nervous system therapies," Aliada is focused on developing novel therapies for CNS diseases that are traditionally hard to treat due to the complexity of the brain's immune environment. The company has devised a highly versatile platform that has shown promising results in non-human primates, demonstrating proof of concept. This platform encompasses a wide range of modalities, including monoclonal antibodies, enzymes, oligonucleotides, peptides, and other proteins, with a customizable delivery technology tailored for CNS tissue and target localization. Aliada's unique approach involves binding two distinct transport targets on the blood-brain barrier, enabling effective delivery of therapeutic compounds to the CNS. In addition to its platform, Aliada is leveraging its innovative technology to develop specific CNS target antibody binders and is progressing these programs through preclinical evaluation. Established in 2021, Aliada has garnered significant attention in the biotechnology, healthcare, and life sciences industries. The company recently secured a substantial $32.00M investment through a Venture Round at 30 December 2022, indicative of the confidence and interest from potential investors in its groundbreaking approach to CNS drug development.

Business keywords: biologics, CNS drug development, blood-brain barrier crossing, therapeutic antibodies, NHP proof of concept, oligonucleotide delivery, central nervous system therapies, preclinical evaluation, platform technology, enzyme therapy, customizable delivery technology

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $32.00M -
30 Dec 2022

Aliada Therapeutics Alternatives & Competitors

View All Alternatives
Aliada Therapeutics vs
Travecta Therapeutics
Travecta Therapeutics

Pioneering advancements in central nervous system treatments with innovative solutions for crossing...

Series A
Biotechnology, Health Care
Aliada Therapeutics vs
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. United States

Creating breakthrough innovative therapeutics for serious CNS disorders

Series C
144 employees
Biopharma, Biotechnology
Aliada Therapeutics vs
ICB International
ICB International

Pioneering breakthrough technology enabling new non-invasive diagnostics and therapeutics for CNS di...

Venture round
Biotechnology, Health Care
Compare Aliada Therapeutics vs ICB International
View all alternatives

FAQ About Aliada Therapeutics

Beyond boundaries: Crossing the blood-brain barrier to create the next generation of central nervous system therapies
Aliada Therapeutics was founded in 2021.
Aliada Therapeutics is headquartered in Boston, United States.
Aliada Therapeutics operates in Biotechnology, Health Care and Life Sciences. Its work centres on biologics, CNS drug development, blood-brain barrier crossing and therapeutic antibodies.
Aliada Therapeutics has approximately 26 employees.
Aliada Therapeutics has completed 1 funding round, raising a total of $32.00M. The latest funding stage is Venture round.
Top alternatives and competitors to Aliada Therapeutics include Travecta Therapeutics, MapLight Therapeutics, Inc., ICB International, SynapCell, Alcyone Lifesciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Aliada Therapeutics and Travecta Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Aliada Therapeutics, https://bouncewatch.com/company/aliada-therapeutics, updated 4 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout